Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Gerber

Showing results (181-190 of 289) with videos related to

Pageof 29
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2020
Experience, Perceptions, and Recommendations Concerning COVID-19-Related Clinical Research AdjustmentsDavid E Gerber, Thomas Y Sheffield, M Shaalan Beg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung CancersEdward A Motea, Xiumei Huang, Naveen Singh, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancersHelena A Yu, Myung-Ju Ahn, Byoung Chul Cho, et al.
The Oncologist|March 28, 2025
Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancerMitchell S von Itzstein, Sawsan Rashdan, Suzanne E Dahlberg, et al.
JCO Oncology Practice|July 29, 2021
Longitudinal Experience With and Impressions of COVID-19-Related Clinical Research ChangesDavid E Gerber, Valerie L Clark, Thomas Y Sheffield, et al.
Clinical Lung Cancer|June 6, 2025
Mortality in a Diverse, Real-World Lung Cancer Screening CohortMary E Gwin, Tanushree Prasad, Urooj Wahid, et al.
BMC Medical Research Methodology|May 21, 2020
A randomized trial of mail and email recruitment strategies for a physician survey on clinical trial accrualCaitlin C Murphy, Simon J Craddock Lee, Ann M Geiger, et al.
Cancer|January 23, 2020
Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminologyMitchell S von Itzstein, Elda Railey, Mary L Smith, et al.
Oncoimmunology|January 10, 2022
Association between immune-related adverse event timing and treatment outcomesDavid Hsiehchen, Abdul Rafeh Naqash, Magdalena Espinoza, et al.
Journal for Immunotherapy of Cancer|August 14, 2023
T-cell tolerant fraction as a predictor of immune-related adverse eventsJared Ostmeyer, Jason Y Park, Mitchell S von Itzstein, et al.
Pageof 29

Showing results (181-190 of 289) with videos related to

Sort By:
Pageof 29
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2020
Experience, Perceptions, and Recommendations Concerning COVID-19-Related Clinical Research AdjustmentsDavid E Gerber, Thomas Y Sheffield, M Shaalan Beg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung CancersEdward A Motea, Xiumei Huang, Naveen Singh, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancersHelena A Yu, Myung-Ju Ahn, Byoung Chul Cho, et al.
The Oncologist|March 28, 2025
Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancerMitchell S von Itzstein, Sawsan Rashdan, Suzanne E Dahlberg, et al.
JCO Oncology Practice|July 29, 2021
Longitudinal Experience With and Impressions of COVID-19-Related Clinical Research ChangesDavid E Gerber, Valerie L Clark, Thomas Y Sheffield, et al.
Clinical Lung Cancer|June 6, 2025
Mortality in a Diverse, Real-World Lung Cancer Screening CohortMary E Gwin, Tanushree Prasad, Urooj Wahid, et al.
BMC Medical Research Methodology|May 21, 2020
A randomized trial of mail and email recruitment strategies for a physician survey on clinical trial accrualCaitlin C Murphy, Simon J Craddock Lee, Ann M Geiger, et al.
Cancer|January 23, 2020
Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminologyMitchell S von Itzstein, Elda Railey, Mary L Smith, et al.
Oncoimmunology|January 10, 2022
Association between immune-related adverse event timing and treatment outcomesDavid Hsiehchen, Abdul Rafeh Naqash, Magdalena Espinoza, et al.
Journal for Immunotherapy of Cancer|August 14, 2023
T-cell tolerant fraction as a predictor of immune-related adverse eventsJared Ostmeyer, Jason Y Park, Mitchell S von Itzstein, et al.
Pageof 29